公开(公告)号：EP2118114B1

公开(公告)日：2012-09-26

申请号：EP08701075.7

申请日：2008-01-04

申请人： Synthon B.V.

发明人： ZHU, Jie ,  KELTJENS, Rolf ,  FIRET, Judith, Janneke

IPC分类号： C07D491/044

CPC分类号： C07D491/044

公开(公告)号：EP2321311B1

公开(公告)日：2012-09-19

申请号：EP09777171.1

申请日：2009-07-10

申请人： Synthon B.V.

发明人： BARTL, Jiri ,  BENOVSKY, Petr

IPC分类号： C07D471/04

CPC分类号： C07D471/04

公开(公告)号：EP2490675A1

公开(公告)日：2012-08-29

申请号：EP09741235.7

申请日：2009-10-22

申请人： Synthon B.V.

发明人： OSINGA, Niels, Jaap

IPC分类号： A61K9/20 ,  A61K9/28 ,  A61K31/785

CPC分类号： A61K9/2018 ,  A61K9/2853 ,  A61K31/785

摘要： The invention relates to a pharmaceutical immediate release tablet comprising a core comprising 70-85 weight percent of sevelamer carbonate, calculated as an anhydrous compound, 10-25 weight percent of lactose monohydrate and, optionally, a water soluble film coat surrounding the to a process of making such tablets, to their use in medicine, and to the use of polyvinyl alcohol-polyethylene glycol graft copolymer for making such coated tablets.

公开(公告)号：EP2062881B1

公开(公告)日：2011-02-23

申请号：EP07022670.9

申请日：2007-11-22

申请人： Synthon B.V.

发明人： Zhu, Jie

IPC分类号： C07D295/205 ,  C07D295/073

CPC分类号： C07D295/205 ,  C07D295/073

公开(公告)号：EP2242483A1

公开(公告)日：2010-10-27

申请号：EP08865203.7

申请日：2008-12-18

申请人： Synthon B.V.

发明人： JANSEN, Korinde Annemarie

IPC分类号： A61K9/20 ,  A61K31/4535

CPC分类号： A61K9/2054 ,  A61K9/2018 ,  A61K9/2027 ,  A61K9/2077 ,  A61K31/4535

摘要： A pharmaceutical composition comprising raloxifene or a pharmaceutically acceptable salt thereof, a mixed cellulose excipient, and a disintegrant can be conveniently made.

公开(公告)号：EP2015735A1

公开(公告)日：2009-01-21

申请号：EP07724657.7

申请日：2007-04-20

申请人： Synthon B.V.

发明人： VAN DEN HEUVEL, Dennie, Johan, Marijn

IPC分类号： A61K9/50 ,  A61K31/135

CPC分类号： A61K9/5078 ,  A61K9/5089 ,  A61K31/135 ,  A61K31/137

摘要： Controlled release tolterodine beads are formed of a sugar core, an innermost sealcoat layer comprising HPMC, a tolterodine drug layer, and an outer control release layer. The thickness of the hydrophilic HPMC sealcoat layer can be used help modulate the release of the tolterodine drug.

公开(公告)号：EP1988086A1

公开(公告)日：2008-11-05

申请号：EP08075311.4

申请日：2008-04-22

申请人： Synthon B.V.

发明人： Zhu, Jie

IPC分类号： C07D307/87

CPC分类号： C07D307/87

摘要： The invention relates to an (S)-enriched citalopram tartrate compound, wherein at least 70% of the citalopram moieties are the (S)-enantiomer of citalopram.

摘要翻译： 本发明涉及一种富含（S）的西酞普兰酒石酸盐化合物，其中至少70％的西酞普兰部分是西酞普兰的（S） - 对映异构体。

公开(公告)号：EP1984371A1

公开(公告)日：2008-10-29

申请号：EP07703294.4

申请日：2007-02-02

申请人： Synthon B.V.

发明人： ZHU, Jie

IPC分类号： C07D487/04

CPC分类号： C07D487/04

摘要： The invention relates to an S-zopiclone-L-tartrate compound, to a process, which comprises reacting a mixture of R- and S-zopiclone and/or a salt thereof with L-tartaric acid in a solvent to form a solution containing zopiclone ions and L-tartaric acid ions, to a process for increasing the enantiomeric purity of S-zopiclone, which comprises: (a) selectively precipitating from a solution, which contains zopiclone and tartaric acid as solutes and acetonitrile as a solvent, an S-zopiclone-L-tartrate acetonitrile solvate; and (b) treating said S-zopiclone-L-tartrate acetonitrile solvate with a base to form enriched S-zopiclone and to the use of L-tartaric acid in the making of enriched S-zopiclone and/or its L-tartrate compound.

公开(公告)号：EP1858894A1

公开(公告)日：2007-11-28

申请号：EP06707626.5

申请日：2006-03-16

申请人： Synthon Argentina S.A. ,  Synthon B.V.

发明人： COMIN, Jorge, Humberto, Zenon ,  REVELLI, Gustavo, Ariel ,  BARDI, Fernando, Gabriel

IPC分类号： C07D457/06 ,  C07F7/10

CPC分类号： C07D457/04 ,  C07D457/06 ,  C07F7/10

摘要： The invention relates to a process for preparing cabergoline of formula (1).

公开(公告)号：EP1858855A1

公开(公告)日：2007-11-28

申请号：EP06723592.9

申请日：2006-03-16

申请人： Synthon B.V.

发明人： ETTEMA, Gerrit, Jan, Bouke ,  WESTHEIM, Raymond, Jozef, Hubertus ,  KALMOUA, Faysal

IPC分类号： C07D215/22

CPC分类号： C07D215/227

摘要： Crystalline aripiprazole Type II can be formed without solid state heat treatment. Instead a liquid is used such as in crystallizing from a solvent, especially 2-propanol, dimethyl sulfoxide, tetrahydrofuran or a combination thereof, or in a solvent mediated solid-solid transformation, typically in ethyl acetate.